secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001420720-24-000012
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio sells PD-1 agonist program to Otsuka for $1M upfront; up to $52.5M milestones
--------------------------------------------------------------------------------

- Otsuka acquired iBio's PD-1 agonist assets; $1M cash at closing, up to $52.5M in development and commercial milestones.
- iBio originally acquired the PD-1 assets from RubrYc Therapeutics in September 2022; no related milestone obligations.
- Deal closes Feb 25, 2024; iBio will redirect resources to its proprietary immuno-oncology pipeline and AI platform.
- PD-1 agonists target autoimmune diseases; CEO Martin Brenner calls transaction a win-win and non-dilutive capital source.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072024000012/0001420720-24-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072024000012/ibio-20240226x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-24-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer